{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:18:33Z","timestamp":1793449113398,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ijantimicag.2018.01.021","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T23:49:24Z","timestamp":1517960964000},"page":"745-751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Population pharmacokinetics\/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy"],"prefix":"10.1016","volume":"51","author":[{"given":"Takeshi","family":"Ide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0010","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl. 4","key":"10.1016\/j.ijantimicag.2018.01.021_bib0015","first-page":"iv7","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2018.01.021_bib0020","first-page":"ii17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/dki014","article-title":"Pharmacokinetic studies of linezolid and teicoplanin in the critically ill","volume":"55","author":"Whitehouse","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jac\/dkm431","article-title":"Effect of severity of sepsis on tissue concentrations of linezolid","volume":"61","author":"Thallinger","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/17425255.2016.1170807","article-title":"Pharmacokinetics of linezolid in critically ill patients","volume":"12","author":"Sazdanovic","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0040","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkv349","article-title":"Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration","volume":"71","author":"Roger","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.05.009","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients","volume":"48","author":"Dong","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijantimicag.2014.07.001","article-title":"Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections","volume":"44","author":"Luque","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0055","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1128\/AAC.01885-13","article-title":"Clinical population pharmacokinetics and toxicodynamics of linezolid","volume":"58","author":"Boak","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0060","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13054-016-1551-7","article-title":"Effects of continuous renal replacement therapy on linezolid pharmacokinetic\/pharmacodynamics: a systematic review","volume":"20","author":"Villa","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0065","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/0091270011417717","article-title":"Linezolid pharmacokinetics in patients with acute renal failure undergoing continuous venovenous hemodiafiltration","volume":"52","author":"Carcelero","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13054-015-0818-8","article-title":"RENAL Replacement Therapy Study Investigators. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics","volume":"19","author":"Roberts","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0075","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa0902413","article-title":"Intensity of continuous renal-replacement therapy in critically ill patients","volume":"361","author":"Bellomo","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0080","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00134-007-0754-4","article-title":"Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators","volume":"33","author":"Uchino","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0085","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0090","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0924-8579(01)00383-1","article-title":"Determination of linezolid in human serum and urine by high-performance liquid chromatography","volume":"18","author":"Borner","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0105","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0110","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1128\/AAC.01694-12","article-title":"Risk factors for a low linezolid trough plasma concentration in acute infections","volume":"57","author":"Morata","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0115","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ijantimicag.2017.04.002","article-title":"Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration","volume":"49","author":"Corcione","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0120","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic drug monitoring of anti-infective agents in critically ill patients","volume":"9","author":"Jager","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2014.01.015","article-title":"The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?","volume":"79","author":"Blot","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/bdd.1910","article-title":"Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients","volume":"35","author":"El-Assal","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0135","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00228-009-0766-9","article-title":"Pharmacokinetics of linezolid in septic patients with and without extended dialysis","volume":"66","author":"Swoboda","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0140","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/cc13984","article-title":"Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study","volume":"18","author":"Zoller","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jac\/dki133","article-title":"Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration","volume":"56","author":"Meyer","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0150","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0155","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0160","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/AAC.01185-10","article-title":"Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients","volume":"55","author":"Sasaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0165","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijantimicag.2007.09.009","article-title":"Linezolid pharmacokinetic\/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion","volume":"31","author":"Adembri","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0170","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/s13054-014-0525-x","article-title":"Therapeutic drug monitoring: linezolid too?","volume":"18","author":"Richards","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0175","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jinf.2015.06.007","article-title":"Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections","volume":"71","author":"Lopez-Garcia","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0180","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0185","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0190","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1097\/CCM.0b013e3181aab3d0","article-title":"Principles of antibacterial dosing in continuous renal replacement therapy","volume":"37","author":"Choi","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/cc13938","article-title":"Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy","volume":"18","author":"Ulldemolins","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.01.021_bib0200","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/cc7093","article-title":"Clinical review: drug metabolism and nonrenal clearance in acute kidney injury","volume":"12","author":"Vilay","year":"2008","journal-title":"Crit Care"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918300323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918300323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T07:27:12Z","timestamp":1535095632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918300323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0924857918300323"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.01.021","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics\/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}